. 2021 Feb 4;27(13):2052–2061. doi: 10.1177/1352458521988926

Table 1.

Subgroup analyses of key secondary endpoints: cumulative number of active MRI lesions, randomized controlled period.

Subgroup	Placebo (N = 56)		Inebilizumab (N = 174)		Analysis
Subgroup	Patients, n/N	Lesions, mean (SD)	Patients, n/N	Lesions, mean (SD)	RR (95% CI)	p value	Interaction test p value
Disease duration < 5 years	25/46	2.3 (1.2)	64/144	1.6 (1.0)	0.555 (0.363–0.849)	0.0066	0.8462
Disease duration ⩾ 5 years	7/10	2.3 (1.7)	15/30	1.9 (1.1)	0.603 (0.259–1.406)	0.2419	0.8462
Baseline EDSS score < 5	22/39	2.5 (1.4)	59/129	1.6 (1.0)	0.538 (0.341–0.848)	0.0076	0.6901
Baseline EDSS score ⩾ 5	10/17	2.0 (1.1)	20/45	1.7 (0.9)	0.643 (0.319–1.295)	0.2163	0.6901
Prior NMOSD attacks < 4	16/31	1.9 (1.1)	39/93	1.6 (1.0)	0.650 (0.372–1.139)	0.1322	0.4503
Prior NMOSD attacks ⩾ 4	16/25	2.8 (1.3)	40/81	1.7 (1.0)	0.484 (0.288–0.813)	0.0061	0.4503
Time to last attack < 26w	17/33	2.3 (1.3)	48/103	1.6 (0.9)	0.645 (0.378–1.062)	0.0844	0.4460
Time to last attack ⩾ 26w	15/23	2.3 (1.3)	31/71	1.7 (1.2)	0.476 (0.265–0.855)	0.0130	0.4460
White	15/28	2.3 (1.3)	37/92	1.3 (0.5)	0.428 (0.254–0.722)	0.0015	0.1887
Non-White	17/28	2.4 (1.3)	42/82	1.9 (1.3)	0.709 (0.416–1.209)	0.2065	0.1887
Asian	6/8	1.7 (0.8)	21/39	2.0 (1.1)	0.886 (0.385–2.043)	0.7772	0.2638
Non-Asian	26/48	2.5 (1.3)	58/135	1.5 (1.0)	0.489 (0.318–0.752)	0.0011	0.2638
Underweight/healthy	15/29	2.5 (1.4)	39/95	1.9 (1.3)	0.584 (0.316–1.080)	0.0864	0.8479
Overweight/obese	17/27	2.1 (1.2)	38/77	1.4 (0.6)	0.543 (0.344–0.859)	0.0090	0.8479
Prior maintenance therapy, yes	23/38	2.3 (1.3)	56/114	1.7 (1.0)	0.609 (0.393–0.944)	0.0265	0.5903
Prior maintenance therapy, no	9/18	2.4 (1.3)	23/60	1.5 (1.1)	0.493 (0.236–1.030)	0.5930	0.5903

CI: confidence interval; EDSS: Expanded Disability Status Scale; MRI: magnetic resonance imaging; NMOSD: neuromyelitis optica spectrum disorder; RR: rate ratio; SD: standard deviation; w: weeks.